AstraZeneca PLC Share Price and Company Fundamentals
Last traded: Today at 7:16 AM
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Key Metrics
PE ratio
62.05
PB ratio
5.48
Dividend yield
0.03%
Beta
0.17
Market cap
-
Enterprise value
-
Company profile
| Industry / Sector | Drug Manufacturers—General / Healthcare |
|---|---|
| Full time employees | 83500 |
| Website | https://www.astrazeneca.com |
| Mailing address | 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom |
| Phone / Fax | 44 20 3749 5000 / |
Dividends
Dividend yield
0.03%
Dividend amount
£2.90
Payout ratio
134.28%
5Y Avg. yield
2.80%
AstraZeneca PLC paid £2.90 dividend and the ex-dividend date was 23 Feb 2023.The dividend payout ratio is 134.28%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.AZN dividend payout ratio is more than 90% making it difficult for the company to maintain the dividends and increase it year by year.
AZN's forward dividend amount is £2.39 and the forward dividend yield is 2.17%. A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
Company Executives
As of Mar 2023, following are the company executives and directors listed on AstraZeneca PLC.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Pascal Soriot D.V.M., M.B.A. | CEO & Exec. Director | 63 | 4.78M |
| Dr. Aradhana Sarin M.D. | Exec. Director | 47 | 2.73M |
| Ms. Pam P. Cheng | EVP of Operations, IT & Sustainability and Member of External Sustainability Advisory Board | 51 | |
| Mr. Andrew P. Barnett | Head of Investor Relations | ||
| Mr. Jeffrey Pott | CHRO, Chief Compliance Officer, Gen. Counsel & Member of External Sustainability Advisory Board | ||
| Gonzalo Vina | Head of Global Media Relations | ||
| Dr. Menelas Pangalos Ph.D. | EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board | 55 | |
| Dr. Ruud Dobber Ph.D. | Exec. Vice-Pres of BioPharmaceuticals Bus. Unit | ||
| Dr. Susan Mary Galbraith M.D., Ph.D. | Exec. VP of Oncology R&D | 56 | |
| Mr. Leon Wang | Exec. VP of International & China Pres |
Profitability and management effectiveness
Profit margin
7.41%
Operating margin
20.21%
Return on assets
5.55%
Return on equity
8.63%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of AstraZeneca PLC is and its enterprise value is .
The AZN's stocks Beta value is 0.17 making it 83% less volatile compared to LSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
AstraZeneca PLC (LSE:AZN) Frequently Asked Questions
1. What is AstraZeneca PLC's Stock Symbol?
AstraZeneca PLC trades on LSE under the ticker symbol "AZN".
2. What is AstraZeneca PLC's stock price today?
One share of AZN stock can currently be purchased for approximately £11154.
3. How can I contact AstraZeneca PLC?
AstraZeneca PLC's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom. The company can be reached via phone at 44 20 3749 5000.
4. What is AstraZeneca PLC's official website?
The official website of AstraZeneca PLC is https://www.astrazeneca.com.